Background {#Sec1}
==========

Septic shock after lower gastrointestinal tract perforation is one of major causes of abdominal infection, and the mortality has been reported to be 18 to 50% \[[@CR1]--[@CR3]\]. *Clostridioides difficile* (formerly *Clostridium difficile*) infection (CDI) and pneumonia are common complications after abdominal infection \[[@CR4]--[@CR6]\], and these complications are associated with higher mortality in patients with septic shock after lower gastrointestinal tract perforation \[[@CR7], [@CR8]\].

Histamine-2 receptor antagonists (H2RA) and proton pump inhibiter (PPI) play an essential role in stress ulcer prophylaxis in patients with septic shock \[[@CR9], [@CR10]\]. There are several concerns that stress ulcer prophylaxis was associated with CDI \[[@CR11]\] and hospital-acquired pneumonia \[[@CR12]\]. Previous systematic review and meta-analysis suggested that PPI and H2RA showed similar risk of hospital-acquired pneumonia or CDI \[[@CR13], [@CR14]\]. However, clinical heterogeneity between studies included in these meta-analyses was substantial. On the other hand, a retrospective cohort study suggested that the frequency of adverse effects of H2RA may differ from those of PPI \[[@CR14]\]. If the risk of CDI or hospital-acquired pneumonia is different, a lower-risk drug should be selected. However, it is not known whether PPI and H2RA show similar risk of hospital-acquired pneumonia and CDI for patients with septic shock due to lower gastrointestinal tract perforation.

Therefore, the purpose of this study was to compare H2RA and PPI with regard to gastrointestinal bleeding, 28-day mortality, CDI, and hospital-acquired pneumonia for patients with septic shock after lower gastrointestinal tract perforation using a Japanese national inpatient database.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

Data for this study were extracted from the Japanese Diagnosis Procedure Combination database, which is a nationwide administrative claims database with discharge abstracts representing approximately 50% of all admissions to acute care hospitals in Japan. The database includes the following data: (1) patient demographic data; (2) primary diagnosis, comorbidities at admission, post-admission complications during hospitalization coded with the *International Classification of Diseases, 10th revision* (ICD-10) and text written in Japanese language; (3) hospital identification number; (4) dates of surgery, procedures, and drug prescription; (5) discharge status (dead or alive); and (6) dates of hospital admission and discharge \[[@CR15]--[@CR17]\].

Patient data {#Sec4}
------------

We identified patients with septic shock after lower gastrointestinal tract perforation hospitalized between July 2010 and March 2015. We included patients who (1) were diagnosed with septic shock, (2) diagnosed with lower gastrointestinal tract perforation, (3) required open abdominal surgery within 2 days of admission, and (4) used antibiotics within 2 days of admission. Sepsis was defined as having any bacterial or fungal infection at admission based on the Angus criteria \[[@CR1]\] (Additional Table [1](#MOESM1){ref-type="media"}). Definition of sepsis based on the Angus criteria has been validated in several DPC hospitals in Japan (the sensitivity value of 40.4, the specificity value of 83.0, and the positive predictive value of 79.8% for sepsis) \[[@CR18]\]. Septic shock was defined as combination of diagnosis of sepsis and requirement of vasopressors within 2 days of admission \[[@CR19]\]. Lower gastrointestinal tract perforation was identified with ICD-10 codes (K65.0, K63.1, K57.02, K57.03, K57.22, K57.23, K57.42, K57.43, K57.82, and K57.83) in the primary diagnosis or comorbidities at admission. We included patients who underwent open abdominal surgery within 2 days of admission because patients sometimes receive surgery on the next day if a patient is admitted late at night. Exclusion criteria were as follows \[[@CR12]\]: (1) age \< 18 years, (2) discharge within 2 days of admission, (3) pregnancy, (4) human immunodeficiency virus infection or acquired immunodeficiency syndrome, (5) sucralfate use within 2 days of admission, (6) medical history of peptic ulcer, (7) anticoagulant or antiplatelet drug use within 2 days of admission, (8) neither H2RA nor PPI used within 2 days of admission, and (9) both H2RA and PPI used within 2 days of admission.

Study variables {#Sec5}
---------------

The H2RA group was defined as patients who received H2RA within 2 days of admission, whereas the PPI group was defined as patients who received PPI within 2 days of admission. Other variables included age, sex, ICU admission within 2 days of admission, high care unit (HCU) admission within 2 days of admission, hospital type (academic or not), hospital volume, and Japan coma scale (JCS). Age was categorized at 10-year intervals. Hospital volume was defined as the annual mean number of patients with lower gastrointestinal tract perforation requiring open abdominal surgery. The JCS score was recorded in all patients to assess the level of consciousness on admission, and it correlated well with the Glasgow Coma Scale \[[@CR20]\]. JCS scores were divided into 4 categories: 0 (alert), 1--3 (delirium), 10--30 (somnolence), and 100--300 (coma) \[[@CR20], [@CR21]\]. The use of the following procedures within 2 days of admission were also evaluated: mechanical ventilation, intermittent and continuous renal replacement therapy, polymyxin B hemoperfusion, central venous catheter insertion, vasopressor use, transfusions (red cells, platelet concentrates, fresh-frozen plasma), antithrombin, recombinant human soluble thrombomodulin, immunoglobulin, danaparoid, hydrocortisone, primary use of antibiotics (penicillin, ampicillin, ampicillin/sulbactam, piperacillin/tazobactam, first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin with or without effects for *Pseudomonas aeruginosa*, fourth-generation cephalosporin, carbapenem, aminoglycoside, fluoroquinolone, clindamycin, macrolide, tetracycline, anti-methicillin-resistant *Staphylococcus aureus* drugs and antifungal drugs), and two or more classes of initial antibiotic combinations.

Outcomes {#Sec6}
--------

Outcomes of interest in this study were gastrointestinal bleeding (ICD-10 code: K25, K26, K27, K28, K29, K920, and K922) requiring endoscopic hemostasis within 28 days of admission, 28-day mortality, CDI (ICD-10 code: A047) coded as a complication during hospitalization, and hospital-acquired pneumonia.

Statistical analysis {#Sec7}
--------------------

Descriptive statistics were presented before and after propensity score matching. Continuous variables were presented as the mean with standard deviation (SD). Categorical variables are presented as numbers with percentages.

One-to-one propensity score matching was used to adjust for differences in baseline characteristics and the severity of condition at admission between the H2RA and PPI groups. The probability that a patient received H2RA was modeled for confounders for the following characteristics: age, age category, sex, hospital type, hospital volume, comorbidities at admission, use of mechanical ventilation, intermittent and continuous renal replacement therapy, polymyxin B hemoperfusion, central venous catheter insertion, vasopressor use, transfusion, antithrombin, recombinant human soluble thrombomodulin, immunoglobulin, low molecular heparin, danaparoid, hydrocortisone, primary use of antibiotics, and use of two or more initial antibiotics. Differences between the H2RA and PPI groups before and after propensity score matching were assessed by standardized mean differences \[[@CR22]\]. Absolute standardized mean differences of less than 0.1 were considered as negligible imbalances in the baseline characteristics between the groups \[[@CR23]\]. Fisher's exact test was used to compare outcomes between the two groups. We also estimated the treatment effect using inverse probability of treatment weighting (IPTW) using propensity scores. We calculated risk ratio, risk differences, and their 95% confidence intervals (CI) between unmatched, propensity-matched, and IPTW analyses \[[@CR24]\]. A *P* value of less than 0.05 was considered statistically significant. Propensity score matching was performed using the "matching" package in the statistical software R version 3.1.3 (The R Foundation, Vienna, Austria). IPTW analyses were performed using the "survey" package in the statistical software R version 3.1.3. All other analyses were performed using the IBM SPSS software version 25 (IBM SPSS, Armonk, NY).

Results {#Sec8}
=======

Overall, 3106 patients were identified during the study period. The H2RA group included 1227 patients, and the PPI group included 1879 patients. After one-to-one propensity score matching, 1088 pairs were created (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Flow chart for patient inclusion. *Abbreviations*: H2RA, histamine-2 receptor antagonists; PPI, proton pump inhibiter; HIV, human, human immunodeficiency virus; AIDS, acquired immunodeficiency syndrome

Table [1](#Tab1){ref-type="table"} shows the baseline characteristics of the unmatched (*n* = 3106) and the propensity score-matched groups (*n* = 2176). After propensity score matching, the patients' backgrounds were well-balanced between the H2RA and PPI groups. Table 1Baseline patient characteristics in unmatched and propensity-matched groupsVariablesUnmatched groupMatched groupH2RA groupPPI groupSMDH2RA groupPPI groupSMD*n* = 1227*n* = 1879*n* = 1088*n* = 1088Age, mean (SD)74.5 (13.1)73.7 (13.0)0.0674.2 (13.2)74.4 (12.9)0.02Age category0.090.06 10--191 (0.1)0 (0.0)1 (0.1)0 (0.0) 20--297 (0.7)6 (0.5)5 (0.5)4 (0.4) 30--3919 (1.8)23 (2.0)19 (1.7)19 (1.7) 40--4930 (2.8)39 (3.4)31 (2.8)27 (2.5) 50--5991 (8.6)96 (8.5)82 (7.5)88 (8.1) 60--69198 (18.7)207 (18.3)196 (18.0)196 (18.0) 70--79324 (30.6)342 (30.2)308 (28.3)301 (27.7) 80--89326 (30.8)365 (32.3)364 (33.5)366 (33.6) 90--9962 (5.9)52 (4.6)80 (7.4)85 (7.8) 100--0 (0.0)1 (0.1)2 (0.2)2 (0.2)Sex (female), *n* (%)615 (50.1)891 (47.4)0.05545 (50.1)542 (49.8)0.01ICU admission, *n* (%)449 (36.6)867 (46.1)0.20414 (38.1)434 (39.9)0.04HCU admission, *n* (%)52 (4.2)99 (5.3)0.0550 (4.6)50 (4.6)\< 0.001Hospital type (academic center), *n* (%)240 (19.6)606 (32.3)0.29239 (22.0)206 (18.9)0.08Hospital volume, case/year mean (SD)5.5 (4.9)7.2 (7.4)0.275.7 (5.1)5.7 (5.2)0.01**Comorbidity,*n*(%)** Myocardial infarction16 (1.3)17 (0.9)0.0411 (1.0)9 (0.8)0.02 Congestive heart failure70 (5.7)130 (6.9)0.0565 (6.0)58 (5.3)0.03 Peripheral vascular disease16 (1.3)26 (1.4)0.0114 (1.3)13 (1.2)0.01 Cerebrovascular disease58 (4.7)72 (3.8)0.0447 (4.3)46 (4.2)0.01 Dementia34 (2.8)48 (2.6)0.0128 (2.6)27 (2.5)0.01 Chronic pulmonary disease41 (3.3)52 (2.8)0.0330 (2.8)36 (3.3)0.03 Mild liver disease37 (3.0)70 (3.7)0.0433 (3.0)32 (2.9)0.01 Severe liver disease1 (0.1)7 (0.4)0.061 (0.1)0 (0.0)0.04 Rheumatologic disease30 (2.4)42 (2.2)0.0125 (2.3)24 (2.2)0.006 Hemiplegia or paraplegia2 (0.2)3 (0.2)0.0012 (0.2)1 (0.1)0.03 Diabetes without chronic complications120 (9.8)182 (9.7)0.003104 (9.6)95 (8.7)0.03 Diabetes with chronic complications23 (1.9)43 (2.3)0.0320 (1.8)21 (1.9)0.007 Renal disease71 (5.8)183 (9.7)0.1569 (6.3)69 (6.3)\< 0.001 Any malignancy, including leukemia and lymphoma207 (16.9)300 (16.0)0.02188 (17.3)184 (16.9)0.01 Metastatic solid tumor66 (5.4)96 (5.1)0.0161 (5.6)58 (5.3)0.01**Consciousness level**, *n* (%) Alert925 (75.4)1308 (69.6)0.13808 (74.3)813 (74.7)0.01 Delirium178 (14.5)324 (17.2)0.08167 (15.3)166 (15.3)0.003 Somnolence50 (4.1)100 (5.3)0.0643 (4.0)48 (4.4)0.02 Coma55 (4.5)115 (6.1)0.0753 (4.9)48 (4.4)0.02**Intervention**, *n* (%) Mechanical ventilation667 (54.4)1258 (67.0)0.26625 (57.4)638 (58.6)0.02 Intermittent renal replacement therapy176 (14.3)364 (19.4)0.14170 (15.6)177 (16.3)0.02 Continuous renal replacement therapy23 (1.9)64 (3.4)0.1021 (1.9)21 (1.9)\< 0.001 Polymyxin B hemoperfusion306 (24.9)552 (29.4)0.10284 (26.1)284 (26.1)\< 0.001 Central venous insertion350 (28.5)783 (41.7)0.28335 (30.8)345 (31.7)0.02**Catecholamine**, *n* (%) Dopamine948 (77.3)1213 (64.6)0.28809 (74.4)820 (75.4)0.02 Noradrenaline660 (53.8)1324 (70.5)0.35641 (58.9)631 (58.0)0.02 Vasopressin47 (3.8)143 (7.6)0.1647 (4.3)47 (4.3)\< 0.001 Adrenaline69 (5.6)122 (6.5)0.0465 (6.0)68 (6.2)0.01**Transfusion,*n*(%)** Red cell transfusion379 (30.9)733 (39.0)0.17361 (33.2)369 (33.9)0.02 Platelets transfusion54 (4.4)142 (7.6)0.1352 (4.8)58 (5.3)0.03 Fresh frozen plasma transfusion327 (26.7)471 (25.1)0.04288 (26.5)292 (26.8)0.01 Antithrombin, *n* (%)245 (20.0)463 (24.6)0.11234 (21.5)232 (21.3)0.004 Recombinant human soluble thrombomodulin, *n* (%)198 (16.1)383 (20.4)0.11190 (17.5)192 (17.6)0.005 Immunoglobulin, *n* (%)457 (37.2)735 (39.1)0.04428 (39.3)393 (36.1)0.07 Albumin, *n* (%)823 (67.1)1369 (72.9)0.13738 (67.8)753 (69.2)0.03Danaparoid, *n* (%)6 (0.5)22 (1.2)0.086 (0.6)10 (0.9)0.04Low-molecular-weight heparin, *n* (%)11 (0.9)27 (1.4)0.0511 (1.0)14 (1.3)0.03Hydrocortisone, *n* (%)155 (12.6)340 (18.1)0.15145 (13.3)145 (13.3)\< 0.001**Initial antibiotics use**, *n* (%)Initial use of two or more342 (27.9)568 (30.2)0.05320 (29.4)329 (30.2)0.02Penicillin0 (0.0)2 (0.1)0.050 (0.0)0 (0.0)\< 0.001Ampicillin0 (0.0)2 (0.1)0.050 (0.0)0 (0.0)\< 0.001Ampicillin/sulbactam27 (2.2)46 (2.4)0.0225 (2.3)27 (2.5)0.01Piperacillin/tazobactam88 (7.2)217 (11.5)0.1586 (7.9)97 (8.9)0.04First-generation cephalosporin47 (3.8)66 (3.5)0.0242 (3.9)45 (4.1)0.01Second-generation cephalosporin499 (40.7)573 (30.5)0.21418 (38.4)419 (38.5)0.002Third-generation cephalosporin without effect for *Pseudomonas aeruginosa*43 (3.5)53 (2.8)0.0440 (3.7)41 (3.8)0.01Third-generation cephalosporin with effect for *Pseudomonas aeruginosa*3 (0.2)8 (0.4)0.033 (0.3)3 (0.3)\<0.001Fourth-generation cephalosporin30 (2.4)44 (2.3)0.0129 (2.7)27 (2.5)0.01Carbapenem753 (61.4)1306 (69.5)0.17703 (64.6)690 (63.4)0.03Fluoroquinolone7 (0.6)11 (0.6)0.0026 (0.6)5 (0.5)0.01Aminoglycoside18 (1.5)18 (1.0)0.0516 (1.5)13 (1.2)0.02Clindamycin50 (4.7)40 (3.5)0.0641 (3.8)45 (4.1)0.02Tetracycline1 (0.1)5 (0.3)0.041 (0.1)2 (0.2)0.03Macrolide0 (0.0)7 (0.4)0.090 (0.0)0 (0.0)\< 0.001Anti-MRSA drug20 (1.6)62 (3.3)0.1120 (1.8)20 (1.8)\< 0.001Antifungal drug4 (0.3)14 (0.7)0.064 (0.4)5 (0.5)0.02*H2RA* histamine-2 receptor antagonists, *PPI* proton pump inhibiter, *SD* standard deviation, *ICU* intensive care unit, *HCU* high care unit, *MRSssA* methicillin-resistant *Staphylococcus aureus*, *SMD* standardized mean difference

Table [2](#Tab2){ref-type="table"} shows the outcomes of the two groups. Before propensity score matching, there were no significant differences for gastrointestinal bleeding requiring endoscopic hemostasis, 28-day mortality, CDI, and hospital-acquired pneumonia between the groups (Table [2](#Tab2){ref-type="table"}). Table 2Outcomes in the unmatched and propensity-matched groupsUnmatched groupsPropensity-matched groupsH2RA groupPPI group*P*H2RA groupPPI group*P*Outcome, *n* (%)*n* = 1227*n* = 1879*n* = 1088*n* = 1088Gastrointestinal bleeding requiring endoscopic hemostasis8 (0.65)25 (1.33)0.0768 (0.74)14 (1.3)0.28428-day mortality130 (10.6)234 (12.4)0.954123 (11.3)141 (12.9)0.386*Clostridioides difficile* infection10 (0.81)12 (0.64)0.6637 (0.64)5 (0.46)0.774Hospital-acquired pneumonia38 (3.1)64 (3.4)0.68133 (3.0)47 (4.3)0.138*H2RA* histamine-2 receptor antagonists, *PPI* proton pump inhibiter

After propensity score matching, there were no significant differences between the groups for gastrointestinal bleeding requiring endoscopic hemostasis within 28 days of admission (0.74% vs 1.3%, *P* = 0.284), 28-day mortality (11.3% vs 12.9%, *P* = 0.386), CDI (0.64% vs 0.46%, *P* = 0.774), and hospital-acquired pneumonia (3.0% vs 4.3%, *P* = 0.138) (Table [2](#Tab2){ref-type="table"}). Risk differences in the unmatched, propensity score-matched, and IPTW analysis groups showed similar results (Additional Table [2](#MOESM2){ref-type="media"} and additional Table [3](#MOESM3){ref-type="media"}).

Table [3](#Tab3){ref-type="table"} shows risk ratios of the two groups. Before and after propensity score matching, there were no significant differences for gastrointestinal bleeding requiring endoscopic hemostasis, 28-day mortality, CDI, and hospital-acquired pneumonia between the groups (Table [3](#Tab3){ref-type="table"}). Table 3Risk ratios in the unmatched and propensity-matched groupsOutcomesUnmatched groups (95% CI)Propensity-matched groups (95% CI)Gastrointestinal bleeding requiring endoscopic hemostasis0.49 (0.22--1.08)0.57 (0.24--1.36)28-day mortality0.85 (0.70--1.04)0.87 (0.70--1.09)*Clostridioides difficile* infection1.28 (0.55--2.94)1.40 (0.45--4.40)Hospital-acquired pneumonia0.91 (0.61--1.35)0.70 (0.45--1.09)*CI* confidence interval

Discussion {#Sec9}
==========

In this retrospective study using a national inpatient database of Japan, there were no significant differences in gastrointestinal bleeding requiring endoscopic hemostasis within 28 days of admission, 28-day mortality, CDI, and hospital-acquired pneumonia between the H2RA and PPI groups in patients with septic shock after lower gastrointestinal perforation.

It is controversial whether H2RA increases gastrointestinal bleeding compared with PPI \[[@CR13], [@CR14]\]. The effect of pharmacological acid suppression of H2RA was reported to be lower than that of PPI for treating active gastrointestinal bleeding \[[@CR25]\]. However, H2RA reaches the target pH for stress ulcer prophylaxis within a day in approximately 65% of patients \[[@CR26]\] and may be sufficient for stress ulcer prophylaxis. Thus, gastrointestinal bleeding requiring endoscopic hemostasis was not different between the groups.

It is unknown whether H2RA increases the risk of CDI compared with PPI. Gastric acid functions as a physiological barrier; however, H2RA and PPI altered these barrier mechanisms and were associated with bacterial overgrowth \[[@CR27]\]. However, Clostridium species are usually acid-resistant and cells remain viable at gastric pH levels \[[@CR28]\]; therefore, H2RA and/or PPI may not be associated with the increased risk of CDI. These points may also explain our results.

It is controversial whether H2RA increases the risk of hospital-acquired pneumonia compared with PPI. A gastric pH \> 4 was associated with bacterial overgrowth and colonization and was associated with hospital-acquired pneumonia \[[@CR29]\]. Although the pharmacological acid suppression of H2RA may be lower than that of PPI, both H2RA and PPI induced pH \> 4 within 1 day of administration \[[@CR26]\]. Therefore, the frequency of hospital-acquired pneumonia by H2RA may be similar to that of PPI.

Our study had several strengths. To the best of our knowledge, it is the first study to evaluate the effect of H2RA compared with PPI in patients with septic shock after lower gastrointestinal tract perforation. Second, our study design was based on a real-world clinical setting and included approximately 50% of inpatients who were admitted to acute-care hospitals in Japan.

Our study had several limitations. First, the database lacks laboratory data such as lactate and clinical records including the results of cultures and susceptibility to peritonitis pathogens. Second, in Japan, patients with septic shock after lower gastrointestinal tract perforation were treated on general wards, and our results may not be generalized to other countries. Third, the present study could not assess mild-to-moderate gastrointestinal bleeding without requiring endoscopic hemostasis because the database did not include information regarding this status. Fourth, the database does not include information about initiation time of drug administration. Several procedures or drug administrations might have been performed before H2RA and PPI administration. Fifth, 28-day mortality in the present study was relatively low compared to those in previous studies. The difference may be due to exclusion of patients who died within 2 days of admission in the present study. Sixth, CDI or hospital-acquired pneumonia might have been underestimated, which could have led to less statistical power. Seventh, we defined sepsis using Angus criteria, which was validated in the DPC database. Although specificity of this definition was high, low sensitivity of sepsis may preclude extrapolation to other population. Last, although we used propensity score matching to adjust for patient backgrounds, unmeasured confounding factors might have biased our results.

Conclusions {#Sec10}
===========

In our study, H2RA were not associated with CDI, gastrointestinal bleeding requiring endoscopic hemostasis, 28-day mortality, or hospital-acquired pneumonia compared with PPI in patients with septic shock after lower gastrointestinal tract perforation.
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AIDS

:   Acquired immunodeficiency syndrome

CDI

:   *Clostridioides difficile* infection

CI

:   Confidence interval

HCU

:   High care unit

HIV

:   Human immunodeficiency virus

H2RA

:   Histamine-2 receptor antagonists

ICD-10

:   International Classification of Diseases, Tenth Revision

IPTW

:   Inverse probability of treatment weighting

MRSA

:   Methicillin-resistant *Staphylococcus aureus*

PPI

:   Proton pump inhibitor

SD

:   Standard deviation

SMD

:   Standardized mean difference
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